Health and Healthcare Systems

We could soon have a vaccine to fight the Zika virus

Research scientist Dan Galperin works on Purified Recombinant Zika Enveloped Protein at his laboratory where they are working on developing a vaccine for the Zika virus based on production of recombinant variations of the E protein from the Zika virus at the Protein Sciences Inc. headquarters in Meriden, Connecticut, U.S., June 20, 2016. Picture taken June 20, 2016. REUTERS/Mike Segar - S1BEUEYZGUAA

The Inovio-GeneOne shot is a synthetic vaccine made by reproducing sections of the Zika virus genome in a lab. Image: REUTERS/Mike Segar

Reuters Staff
Our Impact
What's the World Economic Forum doing to accelerate action on Health and Healthcare Systems?
The Big Picture
Explore and monitor how Brazil is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:


A DNA-based Zika vaccine from Inovio Pharmaceuticals Inc (INO, -1.95%) and South Korea’s GeneOne Life Science Inc induced anti-Zika immune responses in an early stage human trial, U.S. researchers reported on Wednesday.

Unlike conventional vaccines, which often use inactivated or killed versions of a virus, the Inovio-GeneOne shot is a synthetic vaccine made by reproducing sections of the Zika virus genome in a lab, and then loading them onto a ring of genetic material called a plasmid.

This vaccine is then injected beneath the skin and followed up with a device that generates electrical impulses, creating small pores in cells that allow the DNA to pass into cells.

After three doses of the Zika vaccine known as GLS-5700, all 40 healthy volunteers in the study developed Zika-specific antibodies.

“Everybody made antibodies,” said Dr. Pablo Tebas, an infectious disease expert at the University of Pennsylvania who led the study.

To see if these antibodies could be protective against the virus, blood from immunized study participants was injected into mice who were then exposed to Zika. Animals that had received the Zika-specific antibodies were protected.

“When we gave mice serum from the same people before they got the vaccine, they were not protected. The mice died,” Tebas said in a telephone interview.

Tebas said the study shows how nimble synthetic DNA vaccines can be, noting that it took just seven months from the time the vaccine was first designed until the start of the clinical trial. “This technique of making DNA vaccines is very fast,” he said.

More testing will be needed to show the vaccine is effective at protecting people from Zika, and that could prove challenging given that the once explosive epidemic has slowed and there are few large populations now at risk for Zika infection.

Zika caused thousands of cases of the birth defect known as microcephaly in Brazil in 2015, prompting the World Health Organization to declare Zika a public health emergency in February 2016. Last November, the WHO dropped the emergency designation, but stressed that the virus, found in at least 60 countries, will keep spreading where mosquitoes that carry the virus are present.

Image: Health Map

Last month, Sanofi SA sanofi-s-a ended development efforts on its Zika vaccine, based on an inactivated or killed Zika virus. Takeda Pharmaceutical Co (TKPYY, +0.22%) is still working on a Zika vaccine using this approach.

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Related topics:
Health and Healthcare SystemsFourth Industrial Revolution
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

Here’s how reducing malaria can add $16 billion to Africa’s GDP every year

Michelle Meineke

June 20, 2024

About Us



Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum